Jump to content

Onternabez: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
→Inflammation and immune modulation: section deleted. content all in vitro, animal model, or general refs with no mention of HU-308. Hence, not WP:MEDRS
No edit summary
Tags: Visual edit Mobile edit Mobile web edit
 
(24 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{{Undisclosed paid|date=November 2021}}

{{short description|Cannabidiol-derivative drug}}
{{short description|Cannabidiol-derivative drug}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
| Watchedfields = changed
| Watchedfields = changed
| class = [[CB2 receptor|CB<sub>2</sub> receptor agonist]]
| verifiedrevid = 426291380
| verifiedrevid = 426291380
| IUPAC_name = [(1''R'',2''R'',5''R'')-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol
| IUPAC_name = [(1''S'',2''S'',5''S'')-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol
| image = HU-308.png
| image = Onternabez.svg
| caption =
| caption =
| width =
| width = <!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = Class B
| legal_US = Unscheduled <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> <BR>
| legal_US_comment =
| legal_status = Florida: Schedule I
| routes_of_administration = <!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism = [[Liver]]
| elimination_half-life =
| excretion = Kidneys


<!--Identifiers-->| CAS_number_Ref = {{cascite|correct|CAS}}
<!--Clinical data-->
| CAS_number = 256934-39-1
| tradename =
| UNII_Ref = {{fdacite|correct|FDA}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| UNII = 8I5L034D55
| pregnancy_category =
| ATC_prefix = None
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| ATC_suffix =
| legal_CA = Schedule II
| PubChem = 11553430
| legal_UK = Class B
| ChEBI = 146244
| legal_US = Unscheduled <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> <BR>
| synonyms = HU-308, HU308, PPP-003, ARDS-003
| legal_US_comment =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| legal_status = Florida: Schedule I
| DrugBank =
| routes_of_administration = Injection, oral, eyedrops
| KEGG = D12305

| ChemSpiderID = 8020425
<!--Pharmacokinetic data-->
<!--Chemical data-->| C = 27
| bioavailability =
| H = 42
| protein_bound =
| O = 3
| metabolism = [[Liver]]
| smiles = CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
| elimination_half-life =
| StdInChI = 1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
| excretion = Kidneys
| StdInChIKey = CFMRIVODIXTERW-FDFHNCONSA-N

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 256934-39-1
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 8I5L034D55
| ATC_prefix =
| ATC_suffix =
| PubChem = 5311172
| ChEBI = 146244
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID = 8020425
<!--Chemical data-->
| C = 27 | H = 42 | O = 3
| smiles = CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
| StdInChI = 1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
| StdInChIKey = CFMRIVODIXTERW-FDFHNCONSA-N
}}
}}


'''HU-308''' (also known as '''HU308''', '''PPP-003''' and '''ARDS-003''') is a [[cannabidiol]] (CBD)-derivative drug that acts as a potent [[cannabinoid]] [[agonist]]. It is highly selective for the [[cannabinoid receptor type 2|cannabinoid-2 receptor]] (CB<sub>2</sub> receptor) subtype, with a selectivity more than 5,000 times greater for the CB<sub>2</sub> receptor than the [[CB1 receptor|CB<sub>1</sub> receptor]].<ref name="Mechoulam 1990">{{cite journal| vauthors = Mechoulam R, Lander N, Breuer A, Zahalka J |date=1990-04-11|title=Synthesis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative|journal=Tetrahedron Asymmetry|volume=1|issue=5|language=en|pages=315–318|doi=10.1016/S0957-4166(00)86322-3|pmid=|pmc=|issn=|doi-access=free}}</ref><ref name="Hanus et al 1999">{{cite journal | vauthors = Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E | display-authors = | title = HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 96 | issue = 25 | pages = 14228–33 | date = December 1999 | pmid = 10588688 | pmc = 24419 | doi = 10.1073/pnas.96.25.14228 | bibcode = 1999PNAS...9614228H | doi-access = free}}
'''Onternabez''' (also known as '''HU-308''', '''HU308''', '''PPP-003''', and '''ARDS-003''') is a [[Synthetic cannabinoids|synthetic cannabinoid]] that acts as a potent [[cannabinoid]] [[agonist]]. It is highly selective for the [[cannabinoid receptor type 2|cannabinoid-2 receptor]] (CB<sub>2</sub> receptor) subtype, with a selectivity more than 5,000 times greater for the CB<sub>2</sub> receptor than the [[CB1 receptor|CB<sub>1</sub> receptor]].<ref name="Mechoulam 1990">{{cite journal| vauthors = Mechoulam R, Lander N, Breuer A, Zahalka J |date=1990-04-11|title=Synthesis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative|journal=Tetrahedron Asymmetry|volume=1|issue=5|language=en|pages=315–318|doi=10.1016/S0957-4166(00)86322-3|pmid=|pmc=|issn=|doi-access=free}}</ref><ref name="Hanus et al 1999">{{cite journal | vauthors = Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E | display-authors = 6 | title = HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 96 | issue = 25 | pages = 14228–14233 | date = December 1999 | pmid = 10588688 | pmc = 24419 | doi = 10.1073/pnas.96.25.14228 | doi-access = free | bibcode = 1999PNAS...9614228H }}</ref><ref>{{cite web |title=Properties of HU-308 ~ Formula C27H42O3 |url=http://pqr.pitt.edu/mol/CFMRIVODIXTERW-BHIFYINESA-N |website=Pitt Quantum Repository |publisher=University of Pittsburgh Department of Chemistry}}</ref> The [[chemical synthesis|synthesis]] and characterization of onternabez took place in the laboratory of [[Raphael Mechoulam]] at the [[Hebrew University of Jerusalem]] (the HU in HU-308) in the late 1990s. The [[pinene]] dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB<sub>2</sub>-selective agonist in ''in vitro'' and animal studies in 1990<ref name="Mechoulam 1990" /> and 1999.<ref name="Hanus et al 1999" />
</ref><ref>{{cite web |title=Properties of HU-308 ~ Formula C27H42O3 |url=http://pqr.pitt.edu/mol/CFMRIVODIXTERW-BHIFYINESA-N |website=Pitt Quantum Repository |publisher=University of Pittsburgh Department of Chemistry}}</ref> The [[chemical synthesis|synthesis]] and characterization of HU-308 took place in the laboratory of [[Raphael Mechoulam]] at the [[Hebrew University of Jerusalem]] (the HU in HU-308) in the late 1990s. The [[pinene]] dimethoxy-DMH-CBD derivative HU-308 was identified as a potent peripheral CB<sub>2</sub>-selective agonist in studies in 1990<ref name="Mechoulam 1990" /> and 1999.<ref name="Hanus et al 1999" />


==Pharmacology==
==Legal status==
===Neuroinflammation===
HU308 promotes neural [[Progenitor cell|progenitor]] (NP) [[cell proliferation|proliferation]] and [[neurogenesis]] of [[neural stem cells]],<ref>{{cite journal | vauthors = Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I | title = Non-psychoactive CB<sub>2</sub> cannabinoid agonists stimulate neural progenitor proliferation | journal = FASEB Journal | volume = 20 | issue = 13 | pages = 2405–7 | date = November 2006 | pmid = 17015409 | doi = 10.1096/fj.06-6164fje | s2cid = 4885167 | url = https://semanticscholar.org/paper/96b76549d320c082222bc4869d612834b1bfcfd9 }}
</ref> promotes [[neuroprotection]] and neurorepair, activates [[phosphatidylinositol]], and has important implications for neuronal survival under [[Neuroinflammation|neuroinflammatory]] conditions occurring in [[animal model]]s of [[neurodegenerative disease]]s, such as [[multiple sclerosis]], [[Alzheimer disease]], and [[Huntington's disease]],<ref>{{cite journal| vauthors = Fernández-Ruiz J, González S, Romero J, Ramos JA |date=2005|title=Cannabinoids in Neurodegeneration and Neuroprotection. |journal=In: Mechoulam, R.(Ed.), Cannabinoids as Therapeutics (MDT) Birkhaüser Verlag; Switzerland|volume=|issue=|language=en|pages=79–109|issn=|doi-access=}}</ref><ref>{{cite journal| vauthors = Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M |date=Jan 2007|title=Cannabinoid CB<sub>2</sub> receptor: a new target for the control of neural cell survival|journal=Trends Pharmacol Sci|volume=28|issue=1|language=en|pages=39–45|doi=10.1016/j.tips.2006.11.001|pmid=17141334|pmc=|issn=|doi-access=free}}</ref><ref>{{cite journal| vauthors = Esposito G, Scuderi C, Savani C, Steardo L, Jr, De Filippis D, Cottone P, Iuvone T, Cuomo V, Steardo L |date=Aug 2007|title=Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression|journal=British Journal of Pharmacology|volume=151|issue=8|language=en|pages=1272–1279|doi=10.1038/sj.bjp.0707337|pmid=17592514|pmc=2189818|issn=|doi-access=free}}</ref><ref>{{cite journal| vauthors = Fernández-López D, Pazos MR, Tolón RM, Moro MA, Romero J, Lizasoain I, Martínez-Orgado J |date=Sep 2007|title=The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats|journal=Pediatric Research|volume=62|issue=3|language=en|pages=255–60|doi=10.1203/PDR.0b013e318123fbb8|pmid=17622949|pmc=|issn=|doi-access=free}}</ref> and upon acute ischemic [[brain injury]].<ref>{{cite journal | vauthors = Palazuelos J, Ortega Z, Díaz-Alonso J, Guzmán M, and Galve-Roperh I | title = CB<sub>2</sub> Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling | journal = Journal of Biological Chemistry | volume = 287 | issue = 2 | pages = 1198–1209 | date = January 2012 | pmid = 22102284 | doi = 10.1074/jbc.M111.291294 | pmc = 3256884 | doi-access = free }}</ref> [[Attenuation]] of the inflammatory response in the brain has also been reported by activation of CB<sub>2</sub> receptors in a study of [[Pia mater|pial]] vessels forming the blood–brain barrier, using a model of [[lipopolysaccharide]]-induced encephalitis, wherein activation of CB<sub>2</sub> receptors decreased [[adhesion molecules]] in the brain tissue and [[Leukocyte adhesion cascade|leukocyte-endothelial adhesion]] in the pial vessels.<ref>{{cite journal| vauthors = Ramirez SH, Haskó J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahadevan A, Zhang M, Tuma R, Son YJ, Persidsky Y |date=21 March 2012|title=Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions|journal=Journal of Neuroscience|volume=32|issue=12|language=en|pages=4000–16|doi=10.1523/JNEUROSCI.4628-11.2012|pmid=22442067|pmc=3325902|issn=|doi-access=free}}</ref> HU-308 protects both [[liver]] and [[blood vessel]] tissues against hepatic ischemia and reperfusion ([[blood circulatory system]]) injury by attenuating [[oxidative stress]], [[inflammatory response]] and [[apoptosis]] via inhibition of [[TNF-α]].<ref name="Rafesh 2007a">{{cite journal| vauthors = Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, et al |date=2007-10-01|title=CB<sub>2</sub>-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion|journal=American Journal of Physiology. Heart & Circulatory Physiology|volume=293|issue=4|language=en|pages=H2210–H2218|doi=10.1152/ajpheart.00688.2007|pmid=17660390|pmc=2229632|issn=|doi-access=free}}</ref> The role of CB<sub>2</sub> receptors in endothelial cell activation and endothelial/inflammatory cell interactions, being critical steps not only in [[reperfusion injury]], but also [[atherosclerosis]] and other inflammatory disorders, is very important, because selective CB<sub>2</sub> cannabinoid agonist HU-308 decreased TNF-α-induced [[ICAM-1]] and [[VCAM-1]] expression in human liver [[sinusoidal endothelial cells]] (HLSECs) expressing CB<sub>2</sub> receptors, as well as the adhesion of human [[neutrophils]] to HLSECs ''[[in vitro]]''.<ref>{{cite journal| vauthors = Pacher P, Gao B |date=Apr 2008|title=Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases|journal=Am J Physiol Gastrointest Liver Physiol|volume=294|issue=4|language=en|pages=G850–G854|doi=10.1152/ajpgi.00523.2007|pmid=18239059|pmc=2376822|issn=|doi-access=free}}</ref> HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity.<ref name="Hanus et al 1999" /><ref>{{cite journal | vauthors = LaBuda CJ, Koblish M, Little PJ | title = Cannabinoid CB<sub>2</sub> receptor agonist activity in the hindpaw incision model of postoperative pain | journal = European Journal of Pharmacology | volume = 527 | issue = 1–3 | pages = 172–4 | date = December 2005 | pmid = 16316653 | doi = 10.1016/j.ejphar.2005.10.020 }}</ref> [[Cannabidiol]] (CBD) and its potent derivatives (like HU-308) are generating considerable interest due to their beneficial neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti-inflammatory and pain-relieving properties, and the CBD scaffold has become of increasing interest for medicinal chemists.<ref name="Morales">{{cite journal| vauthors = Morales P, Reggio PH, Jagerovic N |date=2017-06-28|title=An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol|journal=Frontiers in Pharmacology|volume=8|issue=|language=en|pages=422|doi=10.3389/fphar.2017.00422|pmid=28701957|pmc=5487438|issn=|doi-access=free}}</ref>


Onternabez is non-psychoactive and not scheduled at the federal level in the United States.<ref>{{Cite web |url=http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |title=21 CFR — Schedules of controlled substances §1308.11 Schedule I. |access-date=2014-12-17 |archive-date=2009-08-27 |archive-url=https://web.archive.org/web/20090827043725/http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |url-status=dead }}</ref> It is a Schedule I [[controlled substance]] in the state of [[Florida]] making it illegal to buy, sell, or possess there.<ref>{{cite web | url = http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html | work = Florida Statutes | title = Chapter 893 - Drug abuse prevention and control }}</ref>
===ARDS-003===
HU-308 is also known as ARDS-03 for its ARDS-fighting abilities. A collaboration study at the US [[National Institutes of Health]] (NIH) at [[George Mason University]]'s (GMU's) National Center for Biodefense and Infectious Diseases Biomedical Research Laboratory (BRL) is examining ways to prevent lethal ARDS seen in [[COVID-19]] patients.<ref name="forbes1">{{cite web |url=https://www.forbes.com/sites/emilyearlenbaugh/2020/08/20/synthetic-cannabinoid-drug-for-covid-19-approved-for-phase-1-clinical-trials/?sh=83ef66533298 |title=Synthetic Cannabinoid Drug For Covid-19 Approved For Phase-1 Clinical Trials |last=Earlenbaugh |first=Emily |date=August 20, 2020 |website=Forbes |publisher= |access-date=}}</ref><ref>https://s24.q4cdn.com/136309390/files/doc_presentation/2020/12/Tetra-Bio-Pharma-Milestones-Update-Dec.-30-2020.pdf</ref><ref>{{Cite web|url=https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00026458&issuerType=03&projectNo=03122925&docId=4813488|title = Download SEDAR Filings - Code Verification and Accept Terms of Use}}</ref><ref>{{cite press release |author=<!--Not stated--> |title=Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19 |url=https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Targeted-Pharmaceutical--the-George-Mason-University-Partner-on-ARDS-003-to-Prevent--Treat-COVID-19/default.aspx |location=Ottawa, Ontario |publisher=Tetra Bio-Pharma |agency= |date=October 22, 2020 |access-date=}}</ref><ref name="Liotta">{{cite web |url=https://science.gmu.edu/directory/lance-liotta |title=Lance Liotta |website=GMU College of Science}}</ref><ref>{{Cite web|url=https://tetrabiopharma.com/partners/|title=Partners – Tetra Bio-Pharma}}</ref> Regulatory filings show that in late 2020, Tetra Bio-Pharma and Targeted Pharmaceutical designed short-to-mid-term studies to gather additional data on the benefits of ARDS-003 in [[SARS-CoV-2]] infected animal models for the prevention of ARDS in COVID-19.<ref name="SEDAR-17-2-2021">{{cite web |title=SEDAR TBP Annual Report 17 Feb 2021 |url=https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00026458&issuerType=03&projectNo=03174069&docId=4888388&fbclid=IwAR3W82_NAVXYU0QVVyDBfWrZi7qW7KMBol6cweldmB3GXNTlggMrANeKdbo |website=SEDAR |publisher=SEDAR Tetra Bio-Pharma |access-date=20 February 2021}}</ref> A former NIH deputy director is heading the GMU research on ARDS-003, which is a novel, sterile, injectable, optimized, [[nanoemulsion]] form of HU-308 that has successfully undergone safety and [[toxicology]] studies in accordance with USFDA oversight, which were required before submitting an [[investigational new drug]] (IND) application in the US and a clinical trial application (CTA) in Canada for a [[Phase 1 clinical testing|Phase 1 research study]] through the SARS-CoV-2 regulatory fast-track pathway.<ref name="Liotta" /><ref name="TBP ARDS3 News">{{Cite web|url=https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Completes-Major-Milestone-for-COVID-19-Therapeutic/default.aspx|title = Tetra Bio-Pharma Completes Major Milestone for COVID-19 Therapeutic}}</ref> The toxicology program was designed to the standards of the [[International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use|International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use]] (ICH) for enabling a [[First-in-human trial|first-in-human]] clinical trial; and included general toxicology data for two species-specific studies to assess toxicity in major organ systems (cardiovascular, respiratory, and nervous system) and [[genotoxicity]], as well as the [[metabolism]] and [[Pharmacokinetics|pharmacokinetic]] distribution of the drug.<ref name="TBP ARDS3 News" /> Tetra Bio-Pharma is the first [[endocannabinoid system]] (ECS) biotechnology company researching a cannabinoid treatment for ARDS and sepsis linked to COVID-19, pneumonia and other critical conditions, The ARDS-003 pharmaceutical drug gained FDA approval to begin Phase&nbsp;I and Phase&nbsp;II clinical trials in human subjects for the reduction of cytokine storm, sepsis, and ARDS in COVID-19.<ref name="forbes1" /><ref name="TBP ARDS3 News" /> GMU researchers are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models of [[angiotensin-converting enzyme&nbsp;2]] (ACE2) animals infected [[Nasal administration|intranasally]] with SARS-CoV-2 to determine the survival advantage conferred by a therapeutic if an alternate course or dosing strategy needs to be followed, and to determine viral levels on day-three post-infection when [[viral load]] in the lungs is expected to peak.<ref>{{cite web |last1=Narayanan |first1=Aarthi |last2=Liotta |first2=Lance |title=GMU Grant Announcement: Narayanan and Liotta testing therapeutic efficacy of potential COVID-19 treatments |url=https://www.eurekalert.org/pub_releases/2021-02/gmu-nl021921.php |website=EurekAlert! operated by the nonprofit American Association for the Advancement of Science (AAAS) |publisher=George Mason University |access-date=24 February 2021}}</ref> Dalton Pharma is producing the injectable drug for the GMU effort.<ref>{{cite web |last1=Cachapero |first1=Joanne |title=Cannabis and Coronavirus: Sales Surge as the Industry Carries On |url=https://mgretailer.com/cannabis-news/cannabis-and-coronavirus-sales-surge-as-the-industry-carries-on/ |website=MG Retailer |date=27 August 2020 |access-date=28 February 2021 |quote=Canadian cannabis pharmaceutical company Tetra Bio-Pharma recently contracted with Dalton Pharma Services to produce batches of its HU-308 and ARDS-003, which could help to treat severe cytokine reactions.}}</ref>


==Legal status==
== See also ==
* [[Cannabidiol dimethyl ether]]
Tetra Bio-Pharma owns the intellectual property rights to HU-308.<ref>{{cite web |last1=Lynch |first1=Mary |last2=Kelly |first2=Melanie |title=Patent 9549906 Composition & Methods for Treatment of Ocular Inflammation &/or Pain Jan 2017 |url=https://assignment.uspto.gov/patent/index.html#/patent/search/resultAbstract?id=9549906&type=patNum |website=U.S. Patent & Trademark Office |publisher=USPTO, Panag Pharma |access-date=20 February 2021}}</ref><ref>[https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2019/Tetra-Bio-Pharma-Closesthe-Acquisition-of-Panag-Pharma/default.aspx May 2019, Tetra Bio-Pharma Closes the Acquisition of Panag Pharma]</ref>
* [[Cannabidiol diacetate]]

* [[HU-210]]
HU-308 is non-psychoactive and not scheduled at the federal level in the United States.<ref>[http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm 21 CFR — Schedules of controlled substances §1308.11 Schedule I.]</ref> It is a Schedule I [[controlled substance]] in the state of [[Florida]] making it illegal to buy, sell, or possess there.<ref>[http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html Florida Statutes - Chapter 893 - Drug abuse prevention and control]</ref>
* [[HU-320]]
* [[HU-211]]
* [[Nabilone]]
* [[CP 47,497]]


== References ==
== References ==
{{reflist}}
{{reflist}}

{{Cannabinoids}}
{{Cannabinoids}}

== See also ==
* [[HU-210]]
* [[HU-320]]


[[Category:Primary alcohols]]
[[Category:Primary alcohols]]

Latest revision as of 08:24, 16 October 2024

Onternabez
Clinical data
Other namesHU-308, HU308, PPP-003, ARDS-003
Drug classCB2 receptor agonist
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver
ExcretionKidneys
Identifiers
  • [(1S,2S,5S)-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H42O3
Molar mass414.630 g·mol−1
3D model (JSmol)
  • CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
  • InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
  • Key:CFMRIVODIXTERW-FDFHNCONSA-N
 ☒NcheckY (what is this?)  (verify)

Onternabez (also known as HU-308, HU308, PPP-003, and ARDS-003) is a synthetic cannabinoid that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB2 receptor than the CB1 receptor.[1][2][3] The synthesis and characterization of onternabez took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB2-selective agonist in in vitro and animal studies in 1990[1] and 1999.[2]

[edit]

Onternabez is non-psychoactive and not scheduled at the federal level in the United States.[4] It is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess there.[5]

See also

[edit]

References

[edit]
  1. ^ a b Mechoulam R, Lander N, Breuer A, Zahalka J (1990-04-11). "Synthesis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative". Tetrahedron Asymmetry. 1 (5): 315–318. doi:10.1016/S0957-4166(00)86322-3.
  2. ^ a b Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. (December 1999). "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor". Proceedings of the National Academy of Sciences of the United States of America. 96 (25): 14228–14233. Bibcode:1999PNAS...9614228H. doi:10.1073/pnas.96.25.14228. PMC 24419. PMID 10588688.
  3. ^ "Properties of HU-308 ~ Formula C27H42O3". Pitt Quantum Repository. University of Pittsburgh Department of Chemistry.
  4. ^ "21 CFR — Schedules of controlled substances §1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.
  5. ^ "Chapter 893 - Drug abuse prevention and control". Florida Statutes.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Onternabez&oldid=1251466781"